ProfileGDS5678 / 1417651_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 23% 23% 23% 22% 24% 21% 22% 22% 22% 22% 23% 22% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5606523
GSM967853U87-EV human glioblastoma xenograft - Control 22.5264923
GSM967854U87-EV human glioblastoma xenograft - Control 32.5300723
GSM967855U87-EV human glioblastoma xenograft - Control 42.4823
GSM967856U87-EV human glioblastoma xenograft - Control 52.4624122
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.613924
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.523821
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.509722
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4966422
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5085122
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5094122
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5089123
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.517922
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5204922